4.3 Review

Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors

Journal

HAEMOPHILIA
Volume 19, Issue 3, Pages E151-E166

Publisher

WILEY
DOI: 10.1111/hae.12095

Keywords

adjuvant therapy; bypassing therapy; haemophilia A; inhibitors; refractory bleeding

Categories

Funding

  1. Baxter Healthcare Corporation
  2. Baxter Bioscience
  3. Baxter
  4. Bayer
  5. CSL Behring
  6. Octapharma Pharmaceutical Companies
  7. Baxter Healthcare
  8. Bayer Healthcare
  9. NovoNordisk
  10. Pfizer
  11. Biogen Idec
  12. Octapharma

Ask authors/readers for more resources

In haemophilia patients with well-established high-titer inhibitors, even seemingly minor acute bleeding episodes or surgical procedures may become refractory to treatment and transform into limb- or life-threatening situations. In the absence of evidence-based treatment guidelines, this article presents 10 cases of difficult to control acute and surgical bleeding and offers consensus opinions regarding their management from a panel of experienced haemophilia treaters.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available